Chalcogen Attached Indirectly To The Polycyclo Ring System By Nonionic Bonding Patents (Class 548/260)
  • Patent number: 10526296
    Abstract: Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxyphenyl naphthotriazole structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxyphenyl naphthotriazole structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Shivkumar Mahadevan, Leilani K. Sonoda, Dola Sinha, Patricia Martin
  • Patent number: 9957255
    Abstract: A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Daniel Christopher Brookings, Boris Kroeplien
  • Patent number: 9587070
    Abstract: A method of creating biocompatible polymeric structures includes the steps of: providing a biocompatible polymer including a strained cycloalkyne end group; forming a polymeric structure from the biocompatible polymer such that the strained cycloalkyne end group remains on the biocompatible polymer; providing an azide tethered molecule; and, after forming the polymeric structure, reacting the azide tethered molecule with the cycloalkyne in an azide alkyne cycloaddition reaction to further functionalize the polymeric structure.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: March 7, 2017
    Inventors: Matthew Becker, Jukuan Zheng
  • Patent number: 9034955
    Abstract: The present invention relates to the use of certain benzotriazole derivatives of the general formula (I) where B is an optionally substituted 2-(2-hydroxyphenyl)-2H-benzotriazole group, n is an integer from the range from 3 to 20 and A is an n-valent organic radical, as UV absorber or stabilizer in inanimate organic materials. Furthermore, the invention relates to methods of stabilizing inanimate organic materials, in particular plastics, against the effect of light using specific benzotriazole derivatives. Further subject matters of the invention are certain benzotriazole derivatives and inanimate organic materials comprising certain benzotriazole derivatives.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: May 19, 2015
    Assignee: BASF SE
    Inventors: Sylke Haremza, Andrea Misske, Simon Schambony, Alban Glaser
  • Publication number: 20150051393
    Abstract: A pseudorotaxane, a rotaxane and a catenane are provided. The pseudorotaxane includes at least a macrocyclic host molecule, a guest molecule, and a metal ion. The host molecule contains at least a binding unit and an aromatic linking spacer. The guest molecule has at least a recognition unit. The metal ion is used to template the threading of the guest molecule through the macrocycle host molecule by coordinating to a binding pocket formed from the binding unit of the macrocycle and the recognition moiety of the guest molecule. Rotaxanes or catenanes can be synthesized from the pseudorotaxane complexes, with or without the metal template ion in their molecular structures.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Sheng-Hsien CHIU, You-Han LIN
  • Publication number: 20150031677
    Abstract: Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 29, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Gary H. Posner, Alexander M. Jacobine, Rachel D. Slack, Jennifer R. Mazzone
  • Patent number: 8895754
    Abstract: The invention relates to an improved process for the manufacture of novel benzotriazoles as well to novel benzotriazoles obtained by the novel process. This novel economical process provides products in high purity and yields.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: November 25, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Michael Preschel, Michael Roeder, Alexander Schlifke-Poschalko, Kesheng Zhang
  • Publication number: 20140341776
    Abstract: Thiophene containing water-soluble oligomers were synthesized and characterized. The photophysical properties of these compounds were studied; transient absorption spectroscopy was used to probe the triplet excited state and their ability to sensitize singlet oxygen was spectroscopically monitored in deuterated methanol. The above compounds were tested for their light activated biocidal properties against S. aureus both under UV and visible radiation. Among the oligomers studied, the terthiophene derivative was found to kill the bacteria efficiently.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 20, 2014
    Applicants: STC.UNM, University of Florida Reearch Foundation, Inc.
    Inventors: Kirk S. Schanze, Anand Parthasarathy, Subhadip Goswami, David G. Witten, Eunkyung Ji, Thomas S. Corbitt, Dimitri Dascier
  • Publication number: 20140328777
    Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative, at least one organic UV-filter substance and a cosmetic solvent selected from the group of benzoate solvents such as C12-15 alkyl benzoate. Furthermore, the invention relates to the use of at least one specific benzotriazol derivative for increasing the washability of UV-filter substances in topical compositions comprising a cosmetic solvent selected from the group of benzoate solvents such as C12-15 alkyl benzoate.
    Type: Application
    Filed: June 6, 2012
    Publication date: November 6, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Christine Mendrok-Edinger
  • Publication number: 20140309427
    Abstract: Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.
    Type: Application
    Filed: February 6, 2014
    Publication date: October 16, 2014
    Inventor: Aloke K. DUTTA
  • Patent number: 8829192
    Abstract: Described is the use of specific merocyanine derivatives for protecting body-care and household products from photolytic and oxidative degradation. These compounds perform outstanding UV absorber properties.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: September 9, 2014
    Assignee: BASF SE
    Inventors: Barbara Wagner, Oliver Reich
  • Publication number: 20140243367
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: SIGA TECHNOLOGIES, INC.
    Inventors: Dongcheng DAI, Dennis E. HRUBY, Tove C. BOLKEN, Sean M. AMBERG, Ryan A. LARSON
  • Publication number: 20140221663
    Abstract: Process for the preparation of a benzohetero[1,3]diazole compound disubstituted with heteroaryl groups which comprises reacting at least one benzohetero[1,3]diazole compound disubstituted with at least one heteroaryl compound. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of luminescent solar concentrators (LSC). Furthermore, said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can be advantageously used in the construction of photovoltaic devices such as, for example, photovoltaic cells, photovoltaic modules, solar cells, solar modules, on both a rigid and flexible support. Said benzohetero[1,3]diazole compound disubstituted with heteroaryl groups can also be advantageously used as a precursor of monomeric units in the preparation of semiconductor polymers.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 7, 2014
    Applicant: Eni S.P.A.
    Inventors: Giuliana Schimperna, Gabriele Bianchi
  • Publication number: 20140205551
    Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative and vitamin E or a derivative thereof. Furthermore, the invention relates to compositions that prevent staining of clothes and exhibit a reduced sand adherence on skin.
    Type: Application
    Filed: June 6, 2012
    Publication date: July 24, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Christine Mendrok-Edinger
  • Publication number: 20140088150
    Abstract: The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Douglas C. Beshore, Scott D. Kuduk
  • Publication number: 20140088151
    Abstract: The present invention is directed to hydroxymethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Douglas C. Beshore, Scott D. Kuduk
  • Publication number: 20140088112
    Abstract: The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 27, 2014
    Inventors: Scott D. Kuduk, Jason W. Skudlarek
  • Patent number: 8598078
    Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: December 3, 2013
    Assignee: Syngenta Crop Protection, LLC
    Inventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
  • Patent number: 8585938
    Abstract: UV absorbing compounds that are effective in blocking UV and short-wavelength blue light are disclosed. The UV absorbing compounds are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 19, 2013
    Assignee: Novartis AG
    Inventors: David L. Jinkerson, Walter R. Laredo
  • Publication number: 20130231488
    Abstract: The process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds and the process for preparing siloxane compounds containing 2-hydroxyphenyl benzotriazole function are disclosed.
    Type: Application
    Filed: October 25, 2010
    Publication date: September 5, 2013
    Applicant: L'Oreal
    Inventors: Herve Richard, Jinzhu Xu, Patricio Guerreiro, Yuan Wang, Jianping Guo
  • Publication number: 20130142737
    Abstract: The present invention relates to novel benzotriazoles and to novel topical compositions comprising these benzotriazoles. Furthermore, the invention relates to the use of the novel benzotriazoles as photostabilizer and solubiliser for dibenzoyl-methane derivatives such as Butyl Methoxydibenzoylmethane. In one aspect the invention relates to novel benzotriazoles of formula (Ia) wherein R2 is hydrogen; C1-30alkyl; C1-5alkoxy; C1-5alkoxycarbonyl; C5-7cycloalkyl; C6-10aryl or aralkyl; R3 is hydrogen; C1-5alkyl; C1-5alkoxy or halogen, preferably hydrogen or Cl; R4 is hydrogen or C1-5alkyl; R5 is C1-30alkyl or C5-10cycloalkyl.
    Type: Application
    Filed: January 13, 2011
    Publication date: June 6, 2013
    Inventors: Alexander Schlifkeposchalko, Christine Mendrokedinger, Horst Westenfelder
  • Patent number: 8425891
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: April 23, 2013
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Publication number: 20130074927
    Abstract: The invention provides highly fluorescent materials comprising a single (n=0) or a series (n=1, 2, etc.) of benzo heterocyclic systems. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventor: NITTO DENKO CORPORATION
  • Publication number: 20130011901
    Abstract: The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules.
    Type: Application
    Filed: March 9, 2011
    Publication date: January 10, 2013
    Applicant: JNC CORPORATION
    Inventors: Takamitsu Hosoya, Isao Kii, Suguru Yoshida, Takeshi Matsushita
  • Publication number: 20120329885
    Abstract: The present invention relates to ultraviolet light absorbing compounds having the formula I and compositions containing these compounds in combination with polymers and/or carriers: wherein; R1 is hydrogen or a halogen atom or a straight-chain or branched alkyl group, an alkoxy group or a carboalkoxy group; R2 and R2? can be the same or different and individually are selected from the group consisting of hydrogen, an unsubstituted or substituted straight-chain or branched alkyl group, an alkoxy group, a carboxyalkyl group, a carboalkoxy, a carboxyl group, an hydroxyl group, and a halogen atom. R3, R4 and R5 can be the same or different and individually are selected from the group consisting of hydrogen, a straight-chain or branched alkyl group, an alkylaryl group, an alkoxy group, a phenyl or substituted phenyl group, a cycloalkyl group, a carboalkoxy group, an arylalkyl group, an hydroxyl group and a halogen atom.
    Type: Application
    Filed: June 23, 2011
    Publication date: December 27, 2012
    Inventor: Chia-Hu Chang
  • Patent number: 8324400
    Abstract: This invention is about a material which provides to observe all colors necessary for display technologies in a very small potential range. The material is a derivative of benzotriazole containing donor acceptor type conducting polymer which is soluble, fluorescent and can be used in LEDs, solar cells, electrochromic devices, smart windows and many other technologies.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 4, 2012
    Inventors: Levent Kamil Toppare, Abidin Balan, Derya Baran
  • Patent number: 8323631
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Publication number: 20120302760
    Abstract: The invention relates to an improved process for the manufacture of novel benzotriazoles as well to novel benzotriazoles obtained by the novel process. This novel economical process provides products in high purity and yields.
    Type: Application
    Filed: January 13, 2011
    Publication date: November 29, 2012
    Inventors: Michael Preschel, Michael Roeder, Alexander Schlifke-Poschalko, Kesheng Zhang
  • Patent number: 8308198
    Abstract: The present invention relates to a water-based fluorescent ink for the purpose of measurement or judgment of the fluorescence emission in a visible light region by an excitation wavelength in a predetermined ultraviolet range, containing water, a coloring material dissolved or dispersed in water, and an organic solvent, having a plurality of fluorescent groups in the coloring material structure of the coloring material, and using a water-soluble coloring material having a sulfonic acid group as the water-soluble group in the state of a free acid, capable of improving the water resistance and the light resistance, dramatically increasing the content of the fluorescent coloring material in the ink, which has conventionally been included only by a small amount in the ink due to the concentration quenching problem, obtaining preferable fluorescence emission and water resistance of the recorded image, and providing preferable adhesion resistance to the recording medium of the coloring material and reliability.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 13, 2012
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masako Udagawa, Shoji Koike, Makoto Aoki, Akira Nagashima, Shinichi Hakamada
  • Patent number: 8309554
    Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 13, 2012
    Assignee: Threshold Pharmaceuticals
    Inventors: Jason Lewis, Mark Matteucci, Tao Chen, Hailong Jiao
  • Publication number: 20120245138
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: May 2, 2012
    Publication date: September 27, 2012
    Applicant: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • Patent number: 8273877
    Abstract: Substituted tetraazapentalenes have two benzenoid rings and eight substitutable positions. Substitutions are made of hydrogen or C—H groups in favor of amino groups, nitro groups or nitrogen atoms. The tetraazapentalenes are synthesized through an intermediate azo, which is made from a 1:1:1 molar ratio of a nitroaniline, sodium nitrite and an amine.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: September 25, 2012
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Alfred G. Stern, Patrick A. Caruana
  • Patent number: 8262947
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventor: Walter R. Laredo
  • Patent number: 8262948
    Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Walter R. Laredo, Ali E. Akinay
  • Publication number: 20120130078
    Abstract: Herein, we describe a method for treatment of diabetes and other disorders classified as Metabolic Syndrome. The invention provides novel AMP Deaminase (AMPD) inhibitors comprising novel indazole and benzotriazole derivatives including a phosphorous containing derivative, a carboxylic acid, or an amino acid ester prodrug. The invention also provides support for a novel mechanism of action for the existing drug metformin: direct inhibition of the enzyme AMPD. The inhibition of AMPD in turn activates AMP Kinase, known to be linked to the action of metformin. The invention also makes novel use of a double inhibitor assay allowing identification of selective AMPD inhibitors over ADA inhibitors. The new inhibitors, structurally distinct from metformin, offer selectivity that may obviate side effects known for metformin itself, providing new benefits for diabetes and Metabolic Syndrome.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 24, 2012
    Inventors: Raymond S. Ochs, Tanaji T. Talele
  • Publication number: 20120059095
    Abstract: The present invention relates to the use of certain benzotriazole derivatives of the general formula (I) where B is an optionally substituted 2-(2-hydroxyphenyl)-2H-benzotriazole group, n is an integer from the range from 3 to 20 and A is an n-valent organic radical, as UV absorber or stabilizer in inanimate organic materials. Furthermore, the invention relates to methods of stabilizing inanimate organic materials, in particular plastics, against the effect of light using specific benzotriazole derivatives. Further subject matters of the invention are certain benzotriazole derivatives and inanimate organic materials comprising certain benzotriazole derivatives.
    Type: Application
    Filed: May 11, 2010
    Publication date: March 8, 2012
    Applicant: BASF SE
    Inventors: Sylke Haremza, Andrea Misske, Simon Schambony, Alban Glaser
  • Publication number: 20120053299
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Application
    Filed: July 14, 2011
    Publication date: March 1, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Vladimir V. Popik, Andrei A. Poloukhtine, Jason Locklin
  • Publication number: 20120008228
    Abstract: This invention provides a magnetic recording medium excellent in terms of corrosion resistance. The magnetic recording medium comprises a magnetic recording layer, a protective layer and a lubricant layer provided on a nonmagnetic substrate, and the lubricant layer comprises a compound having a heterocyclic ring.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 12, 2012
    Inventors: Katsumi MABUCHI, Kyoko Honbo, Mina Amo
  • Patent number: 8043607
    Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: October 25, 2011
    Assignee: Novartis AG
    Inventor: David L. Jinkerson
  • Publication number: 20110248217
    Abstract: Disclosed are electroluminescent devices that comprise organic layers that contain dibenzofuran compounds. The compounds are suitable components of, for example, blue-emitting, durable, organo-electroluminescent layers. The electroluminescent devices may be employed for full color display panels in, for example, mobile phones, televisions and personal computer screens.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Inventors: JUNICHI TANABE, Hidetaka Oka, Hiroshi Yamamoto
  • Patent number: 8026372
    Abstract: A process for the preparation of ?-alkoxycarbonylamino-?-aminoacids and ?,? orthogonally diprotected diaminoacids from ?,?-diaminoacids using 1-alkoxycarbonylbenzotriazoles as protecting agents is disclosed. In an alternative embodiment, carbamoylating agents in the presence of benzotriazoles are used instead of 1-alkoxycarbonylbenzotriazoles. This reaction is preferably applied to the preparation of ?-alkoxycarbonyllysines from lysine. A process for the preparation of t-butoxycarbonylbenzotriazoles and novel complexes of ?-alkoxycarbonylamino-?-aminoacids with benzotriazoles are also disclosed.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: September 27, 2011
    Assignee: F.I.S. Fabbrica Italiana Sintetici S.p.A.
    Inventors: Siro Serafini, Riccardo Motterle, Elena Brasola
  • Publication number: 20110190310
    Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Application
    Filed: May 14, 2009
    Publication date: August 4, 2011
    Inventors: Jason Lewis, Mark Matteucci, Tao Chen, Hailong Jiao
  • Publication number: 20110152232
    Abstract: Compounds that modulate GHS-R are described, for examples compounds formula (I)
    Type: Application
    Filed: October 26, 2010
    Publication date: June 23, 2011
    Inventors: Jeffrey O. Saunders, Thomas Coulter, Paul Mortenson, Manuel A. Navia, Jean-Francois Pons
  • Patent number: 7960417
    Abstract: The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 14, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven P. Govek, Jean-Michel Vernier, Theodore Kamenecka, John H. Hutchinson, Richard Pracitto
  • Publication number: 20110064693
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.
    Type: Application
    Filed: August 26, 2008
    Publication date: March 17, 2011
    Inventors: Dongcheng Dai, Dennis E. Hruby, Tove C. Bolken, Sean M. Amberg, Ryan A. Larson
  • Patent number: 7897625
    Abstract: The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 1, 2011
    Assignee: Sanofi-Aventis
    Inventors: Stefan Petry, Gerhard Zoller, Norbert Tennagels, Günter Müller
  • Publication number: 20110038803
    Abstract: A fluorescent probe which specifically and efficiently traps nitrogen monoxide, zinc ion etc. to emit fluorescence is provided. A compound represented by the following general formula (I): [wherein R1 and R2 represent hydrogen atom, or a group represented by the following formula (A): (wherein X1 to X4 represent hydrogen atom, an alkyl group, or a protective group for amino group, and m and n represent 0 or 1); R3 and R4 represent hydrogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R5 to R12 represent hydrogen atom, sulfo group, phospho group, a halogen atom, or a C1-6 alkyl group; R13 and R14 represent a C1-18 alkyl group; Z1 represents oxygen atom, sulfur atom, or —N(R15)— (wherein R15 represents hydrogen atom, or a C1-6 alkyl group); Y1 and Y2 represent —C(?O)—, —C(?S)—, or —C(R16)(R17) (wherein R16 and R17 represent a C1-6 alkyl group); and M? represents a counter ion in a number required for neutralizing the charge].
    Type: Application
    Filed: October 25, 2010
    Publication date: February 17, 2011
    Inventors: Tetsuo NAGANO, Eita SASAKI, Hirotatsu KOJIMA, Tomoya HIRANO, Kazuya KIKUCHI
  • Publication number: 20110024682
    Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising in each case one or more compounds of the formula I in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays containing these media, especially to active-matrix displays and in particular to TN, IPS and FFS displays.
    Type: Application
    Filed: February 25, 2009
    Publication date: February 3, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Markus Czanta, Michael Wittek, Lars Lietzau, Marcus Reuter, Brigitte Schuler
  • Publication number: 20110004301
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Application
    Filed: July 2, 2010
    Publication date: January 6, 2011
    Applicant: Alcon, Inc.
    Inventor: Walter R. Laredo
  • Publication number: 20100331302
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: July 8, 2010
    Publication date: December 30, 2010
    Applicant: Chemocentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna